Lineage Cell Therapeutics Expands Cell Transplant Pipeline With COR1
Benzinga Newsdesk 7 months ago
BiotechNewsGeneral
New Internally-Developed and Wholly-Owned Asset Benefits From Existing Ophthalmology and Manufacturing ExpertiseFuchs Endothelial Corneal Dystrophy (FECD) Afflicts More Than 7.3% of the Population with a Predicted
- New Internally-Developed and Wholly-Owned Asset Benefits From Existing Ophthalmology and Manufacturing Expertise
- Fuchs Endothelial Corneal Dystrophy (FECD) Afflicts More Than 7.3% of the Population with a Predicted 10-Year CAGR of 7.7%